Entacapone dose

Phase 1Small molecule

DDaniel Claassen

Entacapone dose is one of 3 small molecule programs targeting Autonomic Failure. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autonomic FailureRecruiting

Autonomic FailurePhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Autonomic Failure

#DrugCompanyPhaseTrials

Northera

Lundbeck

Phase 1

1 2

Proamatine

Takeda

Phase 1

1 3

Entacapone dose

DDaniel Claassen

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Autonomic Failure

NCT04246437

Clinical

Trials by Indication[1]

Autonomic Failure1 trial

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Recruiting·DDaniel Claassen·Phase 1·NCT04246437·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Entacapone dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Entacapone dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Entacapone dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daniel Claassen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDaniel Claassen

Entacapone dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Autonomic Failure1 trial

References

Drug Info

Quick Facts

Related News